Resultados da busca - Curtis Dunshee

  • Mostrando 1 - 12 resultados de 12
Refinar Resultados
  1. 1
    First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States

    First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United St... por Rana R. McKay, Alicia K. Morgans, Neal D. Shore, Curtis Dunshee, Geeta Devgan, Neeraj Agarwal

    Publicado em 2024
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  2. 2
    Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design

    Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design por Neeraj Agarwal, Arun Azad, Neal D. Shore, Joan Carles, André P. Fay, Curtis Dunshee, Lawrence I. Karsh, M. Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Akos Czibere, Karim Fizazi

    Publicado em 2022
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer

    Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prost... por Neeraj Agarwal, Arun Azad, Neal D. Shore, Joan Carles, André P. Fay, Curtis Dunshee, Lawrence I. Karsh, M. Luisa Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Akos Czibere, Karim Fizazi

    Publicado em 2022
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study

    Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES... por Arnulf Stenzl, Curtis Dunshee, Ugo De Giorgi, B. Yа. Alekseev, Taro Iguchi, Russell Z. Szmulewitz, Thomas W. Flaig, Bertrand Tombal, Robert Morlock, Cristina Ivanescu, Krishnan Ramaswamy, Fred Saad, Andrew J. Armstrong

    Publicado em 2020
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial

    Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer: Data from a 52-Week Clinical Trial por Jose De La Cerda, Laurence Belkoff, Kevin D. Courtney, Elan Diamond, James D’Olimpio, Curtis Dunshee, Lawrence Gervasi, Michael Goodman, Kriti Mittal, David S. Morris, Paul Sieber, Ronald Tutrone, Michael J. Ryan, Yi Zhong, Mike Ufer, Neal D. Shore

    Publicado em 2025
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from a phase III (TALAPRO-2) study

    1811P Patient-reported outcomes (PROs) in men with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) mutations receiving talazoparib... por André P. Fay, Karim Fizazi, Nobuaki Matsubara, Arun Azad, Fred Saad, U.F.F. De Giorgi, Jae Young Joung, Peter C.C. Fong, Robert J. Jones, Stefanie Zschäbitz, Jan Oldenburg, Neal D. Shore, Curtis Dunshee, Joan Carles, Paul Cislo, Jane Chang, Cynthia G. Healy, A. Niyazov, Neeraj Agarwal

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study

    Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study por Arun Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Robert J. Jones, Stefanie Zschäbitz, Jan Oldenburg, Neal D. Shore, Curtis Dunshee, Joan Carles, André P. Fay, Xun Lin, Liza DeAnnuntis, Nicola Di Santo, Michael A. Zielinski, Neeraj Agarwal

    Publicado em 2024
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer

    Plain language summary of the results from the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer por Neeraj Agarwal, Arun Azad, Joan Carles, André P. Fay, Nobuaki Matsubara, Daniel Heinrich, Cezary Szczylik, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Xun Lin, Cynthia G. Healy, Nicola Di Santo, Fabian Zohren, Karim Fizazi

    Publicado em 2024
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologous recombination repair (HRR) status

    1807P Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): Subgroup analyses of the all-comers cohort from TALAPRO-2 by homologou... por Nobuaki Matsubara, Karim Fizazi, Arun Azad, Joan Carles, André P. Fay, U.F.F. De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Lawrence I. Karsh, Philippe Barthélémy, Xun Lin, Cynthia G. Healy, Nicola Di Santo, Fabian Zohren, N. Agarwal

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  10. 10
    First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

    First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial por Karim Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, André P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, Neeraj Agarwal

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  11. 11
    Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

    Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial por Karim Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, André P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, Neeraj Agarwal

    Publicado em 2024
    Obter o texto integral Obter o texto integral
    Errata/Corrigenda
    Salvar na lista
    Na minha lista:
  12. 12
    Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study

    Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the... por Karim Fizazi, Arun Azad, Nobuaki Matsubara, Joan Carles, André P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Éric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, Neeraj Agarwal

    Publicado em 2025
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: